Andrew Technologies, LLC was issued a patent by the US Patent and Trademark Office (USPTO) that provides exclusivity for their Tissue Liquefaction Technology to be used for the removal of visceral fat; the dangerous and metabolically active fat that is attached to the intestines, liver, kidneys and other organs inside the body cavity. This application is currently under investigation by Andrew Technologies, and is not an FDA approved use for the new HydraSolveT Lipoplasty System, which is cleared to remove subcutaneous fat.
HydraSolveT is a novel liposuction device based on the same patented Tissue Liquefaction TechnologyT that was launched in 2003 by Alcon as the AquaLase@ Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. HydraSolveT combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolveT cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolveT achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes.
Dr. Mark S. Andrew, who co-invented Tissue Liquefaction TechnologyT, AquaLase@ Liquefaction Device, and HydraSolveT Lipoplasty System is the Founder and Chief Scientific Officer of Andrew Technologies and has been directly involved in all of the research and development of Tissue Liquefaction Technology for various treatments. According to Dr. Andrew, "the target tissue specificity of our non-cutting Tissue Liquefaction Technology may enable us to safely remove the visceral fat which surrounds the internal abdominal organs as well as the kidneys. Visceral lipectomy of those visceral fat stores, which constitutes the majority of visceral fat in the body, could be a very important future treatment option that may positively impact several of the most common medical problems in the world. We look forward to supporting the appropriate research to develop this exciting application of our liquefaction technology." "Visceral fat has been recognized for its contribution to the metabolic syndrome and type 2 diabetes; but non-greater omentum visceral fat, the visceral fat which surrounds the internal organs in the abdomen as well as around the kidneys, has been virtually impossible to remove with existing technology. We are excited to participate in research that may one day allow us to potentially remove this harmful tissue" Said Dr. Noel N. Williams, Associate Professor of Clinical Surgery and Director, Penn Metabolic & Bariatric Surgery Program at The University of Pennsylvania.
About Andrew Technologies, LLC Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology.
Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.